SYNLOGIC, INC. Debt Securities, Available-for-sale, Amortized Cost
SYNLOGIC, INC. (SYBX) had Debt Securities, Available-for-sale, Amortized Cost of $7.49 million as of 2024-03-31, per its 10-Q filed 2024-05-14.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-03-06
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $7.49M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $23.78M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $8.88M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $0.00.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-03-31 | $7.49M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $23.78M 10-K · filed 2025-03-06 |
| 2023-09-30 | $8.88M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 |
| 2023-03-31 | $31.86M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $61.93M 10-K · filed 2024-03-19 |
| 2022-09-30 | $76.42M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $76.32M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $100.01M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $120.24M 10-K · filed 2023-03-29 |
| 2021-09-30 | $90.62M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $86.21M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $67.64M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $67.92M 10-K · filed 2022-03-17 |
| 2020-09-30 | $75.07M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $77.57M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $94.74M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $100.78M 10-K · filed 2021-03-25 |
| 2019-09-30 | $111.09M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $131.56M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $94.05M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $111.54M 10-K · filed 2020-03-12 |
| 2018-09-30 | $115.42M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $116.66M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $28.59M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |